{"id":"NCT02052596","sponsor":"GlaxoSmithKline","briefTitle":"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-07","primaryCompletion":"2015-06-16","completion":"2016-04-21","firstPosted":"2014-02-03","resultsPosted":"2018-04-24","lastUpdate":"2018-04-24"},"enrollment":935,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster vaccine GSK 1437173A","otherNames":[]},{"type":"BIOLOGICAL","name":"Boostrix","otherNames":[]}],"arms":[{"label":"GSK1437173A Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.","primaryOutcome":{"measure":"Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group","timeFrame":"At 1 month post-Dose 2 (Month 3)","effectByArm":[{"arm":"GSK1437173A Group","deltaMin":361,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":22},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["31443993"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":412},"commonTop":["Pain","Myalgia","Fatigue","Erythema","Headache"]}}